IgA Nephropathy

IgA nephropathy (IgAN), also known as Berger's disease, is a chronic kidney disease characterized by the deposition of immunoglobulin A (IgA) in the glomeruli. This deposition leads to inflammation and damage to the kidney's filtering units, potentially progressing to kidney failure. It is the most common primary glomerulonephritis worldwide.

The precise etiology of IgAN is not fully understood but is believed to be multifactorial, involving genetic predisposition, environmental triggers, and immune dysregulation. Aberrant glycosylation of IgA1, the major antibody subclass deposited, plays a crucial role. This abnormal IgA1 can form immune complexes with anti-glycan antibodies, which then deposit in the glomeruli. Infections, particularly mucosal infections of the respiratory and gastrointestinal tracts, are thought to act as triggers for this immune response. Genetic factors contribute, with variations in certain genes linked to immune regulation and complement pathways identified.

The core of IgAN pathophysiology involves the formation and deposition of IgA-containing immune complexes within the mesangium of the glomeruli. These deposited complexes trigger inflammatory cascades involving complement activation, cytokine release, and recruitment of inflammatory cells. This inflammation leads to mesangial cell proliferation, extracellular matrix expansion, and eventual glomerulosclerosis and tubulointerstitial fibrosis. The chronic inflammation and scarring impair the kidney's ability to filter waste products from the blood, leading to progressive loss of kidney function.

IgAN is the most common cause of primary glomerulonephritis globally. It affects individuals of all ages but is most frequently diagnosed in adolescents and young adults, typically between the ages of 15 and

1. There is a slight male predominance, with men often experiencing more severe disease progression. Prevalence varies geographically, with higher rates reported in individuals of East Asian and European descent.

• Genetic predisposition
• Recurrent infections (especially upper respiratory and gastrointestinal)
• Family history of IgAN
• Certain genetic polymorphisms affecting immune response
• Exposure to environmental triggers (e.g., certain toxins)

A. Early Symptoms

• Microscopic hematuria (blood in urine detected on urine test)


• Asymptomatic proteinuria (protein in urine detected on urine test) B. Common Symptoms


• Gross hematuria (visible blood in urine), often episodic and coinciding with upper respiratory tract infections or gastrointestinal illness


• Mild hypertension


• Occasional flank pain C. Advanced Symptoms


• Edema (swelling), particularly in the legs and ankles


• Worsening hypertension


• Reduced urine output


• Fatigue


• Nausea and vomiting D. Emergency Symptoms


• Rapidly declining kidney function (acute kidney injury)


• Severe hypertension


• Fluid overload with pulmonary edema (shortness of breath)


• Uremic symptoms (confusion, lethargy)

• Vital Signs: Elevated blood pressure is common.
• Inspection: Peripheral edema (pitting edema in lower extremities), possibly ascites or pleural effusions in advanced stages.
• Palpation: Kidneys may be enlarged in rare cases.
• Auscultation: Crackles in the lungs may indicate fluid overload.

A. Clinical Assessment
Detailed medical history, focusing on episodes of gross hematuria, family history of kidney disease, and recent infections. B. Laboratory Testing
Urinalysis, complete blood count, kidney function tests (serum creatinine, BUN), IgA levels, complement levels. C. Imaging Studies
Renal ultrasound to assess kidney size and rule out other causes of kidney disease. D. Functional Tests
Glomerular filtration rate (GFR) estimation. E. Biopsy Findings
Renal biopsy is the gold standard for diagnosis, showing mesangial IgA deposition on immunofluorescence microscopy. F. Genetic Testing
Currently not routinely recommended for diagnosis but may be used in research settings. G. Differential Diagnosis
Distinguishing IgAN from other causes of hematuria and proteinuria, including post-infectious glomerulonephritis, lupus nephritis, IgA vasculitis (Henoch-Schönlein purpura), and thin basement membrane disease.

Test Name: Urinalysis
Type: Urine Test
Purpose: Detects microscopic or gross hematuria, proteinuria, and other abnormalities.
Expected Findings: Red blood cells, red blood cell casts, protein.
Interpretation: Presence and quantification of hematuria and proteinuria are key indicators. Test Name: Serum Creatinine
Type: Blood Test
Purpose: Assesses kidney function by measuring a waste product of muscle metabolism.
Expected Findings: Elevated serum creatinine levels.
Interpretation: Higher levels indicate reduced kidney function. Test Name: Blood Urea Nitrogen (BUN)
Type: Blood Test
Purpose: Measures the amount of urea nitrogen in the blood, another indicator of kidney function.
Expected Findings: Elevated BUN levels.
Interpretation: Elevated levels suggest impaired kidney function. Test Name: Serum IgA Levels
Type: Blood Test
Purpose: Measures the concentration of immunoglobulin A in the blood.
Expected Findings: Elevated serum IgA levels in a significant proportion of patients.
Interpretation: While not diagnostic, elevated IgA is suggestive but not specific to IgAN. Test Name: Estimated Glomerular Filtration Rate (eGFR)
Type: Blood Test (calculated from serum creatinine)
Purpose: Estimates the filtering capacity of the kidneys.
Expected Findings: Reduced eGFR with worsening kidney disease.
Interpretation: A decline in eGFR indicates progressive kidney damage. Test Name: Renal Biopsy
Type: Tissue Biopsy
Purpose: Definitive diagnosis of IgAN through microscopic examination of kidney tissue.
Expected Findings: Immunofluorescence shows IgA deposition in the mesangium; light microscopy may show mesangial hypercellularity, endocapillary hypercellularity, or crescents.
Interpretation: Pathological findings are diagnostic for IgAN.

Renal Ultrasound
Purpose: To assess kidney size, shape, and echogenicity, and to rule out structural abnormalities or obstruction.
Typical Findings: Kidneys may be normal in size or enlarged in early stages; chronic disease can lead to small, echogenic kidneys.
Clinical Importance: Useful for initial assessment and differential diagnosis, but not diagnostic for IgAN.

IgA Nephropathy vs. Post-infectious Glomerulonephritis: Post-infectious GN typically follows a specific infection (e.g., Strep throat) with a characteristic latency period and serological markers. IgAN is often associated with mucosal infections but the hematuria is recurrent and can be prolonged. IgA Nephropathy vs. IgA Vasculitis (Henoch-Schönlein Purpura): HSP is a systemic vasculitis characterized by palpable purpura, arthritis, abdominal pain, and glomerulonephritis with IgA deposition. IgAN is primarily a kidney-limited disease, though systemic manifestations can occur in some cases. IgA Nephropathy vs. Lupus Nephritis: Lupus nephritis is an autoimmune disease involving multiple organs, including the kidneys, with a different pattern of immune deposition (IgG, IgM, C3) on biopsy and specific autoantibodies (e.g., anti-dsDNA).

• Chronic Kidney Disease (CKD)
• End-Stage Renal Disease (ESRD) requiring dialysis or kidney transplantation
• Hypertension
• Edema and fluid overload
• Cardiovascular disease
• Anemia

A. Lifestyle Modifications

• Low-sodium diet to help manage blood pressure and edema.


• Maintain a healthy weight.


• Avoid NSAIDs, which can worsen kidney function. B. Preventive Measures


• Prompt treatment of infections.


• Regular monitoring of blood pressure and kidney function. C. Medical Treatment

The prognosis for IgAN is variable. Approximately 20-30% of patients will progress to end-stage renal disease (ESRD) within 20-25 years of diagnosis. Factors associated with a poorer prognosis include persistent significant proteinuria (>1 g/day), hypertension, reduced kidney function at diagnosis (low eGFR), and specific histological findings on renal biopsy (e.g., crescents, interstitial fibrosis). Early diagnosis and aggressive management of risk factors can significantly improve outcomes.

• Early identification and management of risk factors such as hypertension and proteinuria.
• Regular screening of individuals with a family history of IgAN or recurrent episodes of gross hematuria.
• Prompt management of infections that might trigger episodes of gross hematuria.

The following homeopathic remedies have been historically indicated for symptoms associated with IgA Nephropathy. Selection should be based on individualized symptom totality and constitutional assessment.

• Homeopathy by Hadhrat Mirza Tahir Ahmad (r.a.) — Primary clinical reference
• Robin Murphy — Lotus Materia Medica (3rd Edition)
• William Boericke — Pocket Manual of Homœopathic Materia Medica & Repertory
• ICD-10/ICD-11 Classification — World Health Organization
• Harrison's Principles of Internal Medicine (Reference Standard)

This clinical reference profile is compiled from authoritative medical sources for educational purposes. Always verify clinical data with current medical guidelines.

📊 Advanced Kidney & Renal Function Analyzer

Comprehensive nephrology panel. Calculates eGFR (CKD-EPI 2021 formula), CKD Stage, BUN/Creatinine Ratio, and Creatinine Clearance (Cockcroft-Gault) from a single lab panel.